GORE ANNOUNCES FIRST U.S. ENROLLMENT FOR THE GORE<sup>®</sup> VIAFORT VASCULAR STENT IVC STUDY

CAUTION: Investigational device. Limited by United States law to investigational use.

First U.S. patient enrolled in GORE® VIAFORT Vascular Stent pivotal study.

FLAGSTAFF, Ariz, USA (March 28, 2023) — W. L. Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, non-randomized, multicenter, single-arm study with 5-year follow-up (NCT05409976) to evaluate the investigational GORE® VIAFORT Vascular Stent for the Treatment of Symptomatic Inferior Vena Cava (IVC) Obstruction with or without combined Iliofemoral Obstruction.

"It is exciting to have enrolled the first U.S. patient, an important milestone for venous occlusive disease treatment. With no device options indicated, or frankly designed for both IVC and iliofemoral venous disease, implanting the GORE® VIAFORT Vascular Stent in patients represents a significant step forward in research and ultimately management of these complex patients.”

Kush Desai, M.D.
Northwestern University Feinberg School of Medicine Chicago, IL

The first U.S. patient was enrolled by Kush Desai, M.D. at Northwestern University Feinberg School of Medicine, Chicago, Illinois. “It is exciting to have enrolled the first U.S. patient, an important milestone for venous occlusive disease treatment,” stated Dr. Desai. “With no device options indicated, or frankly designed for both IVC and iliofemoral venous disease, implanting the GORE VIAFORT Vascular Stent in patients represents a significant step forward in research and ultimately management of these complex patients.”

A company press release notes that the GORE VIAFORT Vascular Stent, which has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), utilizes the Gore expanded polytetrafluoroethylene (ePTFE) technology in conjunction with a single wire, sinusoidal-wound nitinol frame. The Gore VIAFORT Vascular Stent IVC study is evaluating the device in a treatment range of 10–28 mm diameter for iliofemoral veins and the IVC. The study is being conducted in the U.S. under an approved investigational device exemption (IDE).

For complete indications and other important safety information for Gore commercial products referenced herein, refer to the applicable Instructions for Use (IFU).

Gore engineers medical devices that treat a range of cardiovascular and other health conditions. With more than 50 million medical devices implanted over the course of more than 45 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives. For more information, visit goremedical.com.

About Gore

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 12,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $4.5 billion.

For more information, visit gore.com.

Media Contact

Teresa Yeoh
W. L. Gore & Associates
M +1 714 466 0327
Contact by email

Products listed may not be available in all markets.

23940600-EN

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.